Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone408-716-4600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$404.90 million
Profitability
Miscellaneous
Employees998
OptionableOptionable
Accuray (NASDAQ:ARAY) Frequently Asked Questions
What is Accuray's stock symbol?
Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How were Accuray's earnings last quarter?
Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings results on Tuesday, January, 22nd. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The medical equipment provider had revenue of $102.32 million for the quarter, compared to the consensus estimate of $104.01 million. Accuray had a negative return on equity of 42.74% and a negative net margin of 5.74%. During the same quarter last year, the business posted ($0.06) EPS. View Accuray's Earnings History.
When is Accuray's next earnings date?
What guidance has Accuray issued on next quarter's earnings?
Accuray updated its FY 2019 earnings guidance on Tuesday, January, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $415-425 million, compared to the consensus revenue estimate of $420.67 million.
What price target have analysts set for ARAY?
4 brokers have issued twelve-month price objectives for Accuray's stock. Their predictions range from $3.90 to $6.00. On average, they expect Accuray's share price to reach $5.30 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Price Targets for Accuray.
What is the consensus analysts' recommendation for Accuray?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.
What are Wall Street analysts saying about Accuray stock?
Here are some recent quotes from research analysts about Accuray stock:
- 1. According to Zacks Investment Research, "Accuray has been gaining from solid demand for Radixact & CyberKnife platforms. Moreover, a recent FDA approval for motion synchronization on the Radixact and the ongoing kVCT imaging are encouraging. Gross orders in the quarter shot up, with significant contribution from APAC regions, especially China. In fact, management foresees tremendous opportunities in China. New products in pipeline are another encouraging factor. The company has kept its fiscal 2019 view intact. On the flip side, contraction in gross margin and persistent operating losses raise concern. Unfavorable product mix, sluggish macroeconomic conditions and pricing issues add to the apprehensions. Accuray faces stiff competition in the radiation oncology space. The company has underperformed the industry in a year. " (2/15/2019)
- 2. BTIG Research analysts commented, "While we were out sick, Accuray posted a ~$6M revenue beat but missed gross order expectations. Although the company fell short of its guided 5% y/y growth in gross orders for FY18, we liked the sales step up, strong revenue guidance for FY19, and the increasing funnel of anticipated multi- system orders. The company’s decision to move away from annual gross order guidance may bother some but is probably the correct move given mgmt’s inability to consistently accurately predict this. Pinning down an order growth rate is likely to become more challenging, as we expect more multi-system orders to add timing unpredictability and more lumpiness to quarterly numbers. Overall, while it may be tougher – at least near term – to get visibility into quarterly orders, we see larger multi-unit bookings as a win for ARAY." (8/22/2018)
Has Accuray been receiving favorable news coverage?
News headlines about ARAY stock have trended positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accuray earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Accuray's key competitors?
Some companies that are related to Accuray include Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), K2M Group (KTWO), Cardiovascular Systems (CSII), Luminex (LMNX), Intersect ENT (XENT), Cryolife (CRY), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX) and OraSure Technologies (OSUR).
Who are Accuray's key executives?
Accuray's management team includes the folowing people:
- Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
- Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
- Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
- Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
- Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer
Who are Accuray's major shareholders?
Accuray's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.57%), Partner Fund Management L.P. (3.13%), Dimensional Fund Advisors LP (2.68%), D. E. Shaw & Co. Inc. (2.29%), Mirae Asset Global Investments Co. Ltd. (2.10%) and Royce & Associates LP (2.09%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kelly Londy, Kevin Waters and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.
Which major investors are selling Accuray stock?
ARAY stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Boston Partners, Mirae Asset Global Investments Co. Ltd., Royce & Associates LP, BlackRock Inc., Bank of America Corp DE, Alambic Investment Management L.P. and Menta Capital LLC. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kevin Waters and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.
Which major investors are buying Accuray stock?
ARAY stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Millennium Management LLC, Two Sigma Investments LP, Mackay Shields LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A. and Acadian Asset Management LLC. View Insider Buying and Selling for Accuray.
How do I buy shares of Accuray?
Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accuray's stock price today?
One share of ARAY stock can currently be purchased for approximately $4.93.
How big of a company is Accuray?
Accuray has a market capitalization of $433.25 million and generates $404.90 million in revenue each year. The medical equipment provider earns $-23,890,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Accuray employs 998 workers across the globe.
What is Accuray's official website?
How can I contact Accuray?
Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]
MarketBeat Community Rating for Accuray (NASDAQ ARAY)
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
